Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae
Specificity of Molecular Fragments Binding to S100B versus S100A1 as Identified by NMR and Site Identification by Ligand Competitive Saturation (SILCS)
Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint
SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation
FOR IMMEDIATE RELEASE: SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation Scientific collaboration demonstrates effective computational method for stabilizing biologic therapeutics such as antibodies December 16, 2020, Baltimore, MD – SilcsBio, LLC, a technology company that develops and markets software and services for structure-based drug design, today announced members […]